

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



dBFT6

Item No. 35385

CAS Registry No.: 1950634-92-0

Formal Name: (6S)-4-(4-chlorophenyl)-N-[8-[[2-[[2-

> (2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]acetyl] aminoloctyl]-2,3,9-trimethyl-6Hthieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]

diazepine-6-acetamide


MF: $C_{42}H_{45}CIN_8O_7S$

FW: 841.4 **Purity:**

UV/Vis.: λ_{max} : 219, 254 nm

A solid Supplied as: -20°C Storage: Stability: ≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

dBET6 is supplied as a solid. A stock solution may be made by dissolving the dBET6 in the solvent of choice, which should be purged with an inert gas. dBET6 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of dBET6 in these solvents is approximately 5, 10, and 15 mg/ml, respectively.

Description

dBET6 is a hybrid compound that drives the selective proteasomal degradation of bromodomaincontaining protein 4 (BRD4).1 It is characterized as a proteolysis-targeting chimera (PROTAC) and contains JQ1, which binds bromo- and extra-terminal (BET) proteins, linked to thalidomide, a ligand for the E3 ubiquitin ligase cereblon. 2 dBET6 binds to BRD4 (IC₅₀ = 14 nM) and induces its degradation when used at a concentration of 100 nM, leading to a global inhibition of transcription in MOLT-4 T cell acute lymphoblastic leukemia (T-ALL) cells. It also reduces leukemic burden in a MOLT-4 T-ALL mouse xenograft model when administered at a dose of 7.5 mg/kg twice per day.

References

- 1. Winter, G.E., Mayer, A., Buckley, D.L., et al. BET bromodomain proteins function as master transcription elongation factors independent of CDK9 recruitment. Mol. Cell 67(1), 5-18 (2017).
- 2. Goracci, L., Desantis, J., Valeri, A., et al. Understanding the metabolism of proteolysis targeting chimeras (PROTACs): The next step toward pharmaceutical applications. J. Med. Chem. 63(20), 11615-11638 (2020).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 10/29/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM